February 12, 2013
FERRING TO HIGHLIGHT PHASE 3 DATA FOR CERVICAL RIPENING CANDIDATE AT SOCIETY FOR MATERNAL-FETAL MEDICINE ANNUAL MEETING
Pivotal data for investigational controlled release misoprostol vaginal insert in the U.S. accepted for presentation
San Francisco, Calif. (February 12, 2013) – Ferring Pharmaceuticals will present pivotal Phase 3 efficacy and safety data from its EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 33rd annual meeting of the Society for Maternal-Fetal Medicine (SMFM) in San Francisco, February 11 – 16. These and other research findings formed the basis for Ferring’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) supporting the use of the controlled release MVI as a treatment option for cervical ripening as part of the labor induction process.
Studies accepted for presentation include
- An oral presentation on Sat., Feb. 16 (9 a.m. – 9:15 a.m. PST), titled “Efficacy and safety of misoprostol vaginal insert compared with dinoprostone vaginal insert for labor induction” (lead author: Deborah A. Wing, MD, University of California, Irvine); and
- A poster presentation on Thurs., Feb. 14 (3:30 p.m. – 5:30 p.m. PST), titled “Comparison of misoprostol vaginal insert and dinoprostone vaginal insert: incidence of treatment-emergent adverse events” (lead author: Stacey Ehrenberg-Buchner, MD, University of Michigan Health System).
*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of EXogenous Prostaglandin comparing the Efficacy and safety of the misoprostol vaginal insert (MVI) 200 mcg to the Dinoprostone vaginal Insert for reducing Time to vaginal delivery in pregnant women at tErm.
For further information, contact: Leila Boukassi MSL New York email@example.com; 646.500.7735
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality biopharmaceutical company, active in global markets. The company identifies, develops and markets innovative products in the areas of general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.